The αv integrin antagonists as novel anticancer agents: An update

Expert Opinion on Investigational Drugs

Volumn 11, Issue 12, 2002, Pages 1765-1774

  Kerr, Janet S ^a   Slee, Andrew M ^a   Mousa, Shaker A ^b  

^a Enanta Pharmaceuticals Inc   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

v 3; v 5 antagonists; Cancer; Integrin

Indexed keywords

10,11 DIHYDRO 3 [3 (2 PYRIDINYLAMINO)PROPOXY] 5H DIBENZO[A,D]CYCLOHEPTENE 10 ACETIC ACID; 3 [[[1 [3 (1H IMIDAZOL 2 YLAMINO)PROPYL] 1H INDAZOL 5 YL]CARBONYL]AMINO] N (MESITYLSULFONYL)ALANINE; ALPHA5 INTEGRIN; ANTINEOPLASTIC AGENT; BETA3 INTEGRIN; CP 4632; DIAGNOSTIC AGENT; L 748415; LOTRAFIBAN; MONOCLONAL ANTIBODY LM 609; SB 223245; SB 267268; SB 273005; SC 56631; SC 65811; SC 69000; SH 306; UNCLASSIFIED DRUG; XT 199; ANGIOGENESIS INHIBITOR; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL ACTIVITY; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE EXPRESSION; HUMAN; INHIBITION KINETICS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOUSE; NONHUMAN; PROTEIN FUNCTION; REVIEW; SKIN CANCER; SOLID TUMOR; TUMOR GROWTH; DRUG ANTAGONISM;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; HUMANS; INTEGRIN ALPHAVBETA3;

EID: 0036904072     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.12.1765     Document Type: Review

References (81)

1. RUOSLAHTI E, PIERSCHBACHER M: Arg-Gly-Asp: A versatile cell recognition sequence. Cell (1986) 44:517-518.
2. HYNES RO: Integrins: versatility, modulation and signaling in cell adhesion. Cell (1992) 69:11-25.
3. COX D, AOKI T, SEKI J, MOTOYAMA Y, YOSHIDA K: The pharmacology of the integrins. Med. Res. Rev. (1994) 14:195-228.
4. ALBELDA SM, BUCK CA: Integrins and other cell adhesion molecules. FASEB J. (1990) 4:2868-2880.
5. CHERESH D: Integrins: structure, function and biological properties. Adv. Mol. Cell Biol. (1993) 6:225-252.
6. SEFTOR EB, SEFTOR EA, HENDRIX MJC: Molecular role(s) for integrins in human melanoma invasion. Cancer Metastasis Rev. (1999) 18:359-375.
7. KOISTINEN P, HEINO J: Integrins in cancer cell invasion. In: Cell Invasion. Heino J, Kahari V-M (Eds.), Eurekah.com, Landes Bioscience, TX, USA (2002):1-27.
8. GUADAGNO TM, OHTSUBO M, ROBERTS JM et al.: A link between cyclin A expression and adhesion dependent cell cycle proliferation. Science (1993) 262:1592-1595.
9. JULIANO R, HASKILL S: Signal transduction from the extracellular matrix. J. Cell Biol. (1993) 120:577-585.
10. 1 integrins. Proc. Natl. Acad. Sci. USA (1991) 88:8392-8395.
11. KORNBERG LJ, EARP HS, PARSONS JT et al.: Cell adhesion or integrin clustering increased phorphorylation of a focal adhesion associated kinase. J. Biol. Chem. (1992) 117:1101-1107.
12. GUAN JL, SHALLOWAY D: Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature (1992) 358:690-692.
13. GIANCOTTI FG, RUOSLAHTI E: Integrin signaling. Science (1999) 285:1028-1032.
14. CALDERWOOD DA, HUTTENLOCHER A, KIOSSES WB et al.: Increased filamin binding to β-integrin cytoplasmic domains inhibits cell migration. Nat. Cell Biol. (2001) 3:1060-1068.
15. HYNES RO: Integrins: Bidirectional, allosteric signaling machines. Cell (2002) 110:673-687.
16. PRICE JT, THOMPSON EW: Mechanism of tumour invasion and metastases: emerging targets for therapy. Expert Opin. Ther. Targets (2002) 6:217-233.
17. ZETTER BR: Angiogenesis and tumor metastasis. Ann. Rev. Med. (1998) 49:407-424.
18. KEELY P, PARISE L, JULIANO R: Integrins and GTPases in tumour cell growth, motility and invasion. Trends Cell Biol. (1998) 8:101-106.
19. FRISCH SM, RUOSLAHTI E: Integrins and anoikis. Curr. Opin. Cell Biol. (1997) 9:701-706.
20. RUOSLAHTI E, ENGVALL E: Integrins and vascular extracellular matrix assembly. J. Clin. Invest. (1997) 99:1149-1152.
21. BROOKS PC: Role of integrins in angiogenesis. Eur. J. Cancer (1996) 32A:2423-2439.
22. 3. Science (2001) 294:339-345.
23. 3 in complex with an arg-gly-asp ligand. Science (2002) 296:151-155.
24. CHERESH DA: Human endothelial cells synthesize and express an Arg-Gly-Asp directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc. Natl. Acad. Sci. USA (1987) 84:6471-6475.
25. LEAVESLEY DI, FERGUSON GD, WAYNER EA et al.: Requirement of integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J. Cell Biol. (1992) 117:1101-1107.
26. WICKHAM TJ, MATHIAS P, CHERESH DA, NEMEROW GR: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell(1993) 73:309-319.
27. ELICEIRI BP, CHERESH DA: Role of alpha v integrins during angiogenesis. Cancer J. (2000) 6:S245-S249.
28. MORETTI S, MARTINI L, BERTI E, PINZI C, GIANNOTTI B: Adhesion molecule profile and malignancy of melanocytic lesions. Melanoma Res. (1993) 3:235-239.
29. SCHADENDORF D, GAWLIK C, HANEY U, OSTMEIER H, SUTER L, CZARNETZKI B: Tumor progression and metastatic behavior in vivo correlates with integrin expression on melanocytic tumors. J. Pathol. (1993) 170:429-434.
30. DANEN EH, JANSEN KF, VAN KRAATS AA, CORNELISSEN IM, RAITER DJ, VAN MUIJEN GN: Alpha v-integrins in human melanoma: gain of alpha v beta 3 and loss of alpha v beta 5 are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice. Int. J. Cancer (1995) 61:491-496.
31. FELDING-HABERMANN B, MUELLER BM, ROMERDAHL CA, CHERESH DA: Involvement of integrin alpha v gene expression in human melanoma tumorigenicity. J. Clin. Invest. (1992) 89:2018-2022.
32. SANDERS LC, FELDING-HABERMANN B, MUELLER BM, CHERESH DA: Role of alpha v integrins and vitronectin in human melanoma cell growth. Cold Spring Harb. Symp. Quant. Biol. LVII (1992) 57:233-240.
33. GLADSON CL, CHERESH DA: Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J. Clin. Invest. (1991) 88:1924-1932.
34. GLADSON CL: Expression of alpha v beta 3 in small blood vessels of glioblastoma tumors. J. Neuropathol. Exp. Neurol. (1996) 55:1143-1149.
35. LIAPIS H, ADLER LM, WICK MR, RADER JS: Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Human Path. (1997) 28:443-449.
36. FELDING-HABERMANN B, MUELLER BM, ROMERDAHL CA, CHERESH DA: Involvement of integrin alpha v gene expression in human melanoma tumorigenicity. Clin. Invest. (1992) 89:2018-2022.
37. PETITCLERC E, STROMBLAD S, VON SCHALSCHA TL et al.: Integrin alpha (v) beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. (1999) 59:2724-2730.
38. SEFTOR RE, SEFTOR EA, GEHLSEN KR et al.: Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc. Natl. Acad. Sci. USA (1992) 89:1557-1561.
39. NIP J, SHIBATA H, LOSKUTOFF D, CHERESH DA, BRODT P: Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin. J. Clin. Invest. (1992) 90:1406-1413.
40. ALBELDA SM, METTE SA, ELDER DE et al.: Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res. (1990) 50:6757-6764.
41. HIEKEN TJ, FAROLAN M, RONAN SG et al.: Beta 3 integrin expression in melanoma predicts subsequent metastasis. J. Surg. Res. (1996) 63:169-173.
42. GASPARINI G, BROOKS PC, BIGANZOLI E et al.: Vascular integrin alpha v beta 3: A new prognostic indicator in breast cancer. Clin. Cancer Res. (1998) 4:2625-2634.
43. MONTGOMERY AMP, REISFELD RA, CHERESH DA: Integrin alpha v beta 3 rescues melanoma cells from apoptosis in a three-dimensional dermal collagen. Proc. Natl. Acad. Sci. USA (1994) 91:8856-8860.
44. FELDING-HABERMANN B, O'TOOLE TE, SMITH JW et al.: Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. USA (2001) 98:1853-1858.
45. FILARDO EJ, BROOKS PC, DEMING SL, DAMSKY C, CHERESH DA: Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J. Cell Biol. (1995) 130:441-450.
46. ARAP W, PASQUALINI R, RUOSLAHTI E: Cancer treatment by targeted drug to tumor vasculature in a mouse model. Science (1998) 279:377-380.
47. DeNARDO SJ, BURKE PA, LEIGH BR et al.: Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother. Radiopharm. (2000) 15:71-79.
48. MARSHALL JF, RUTHERFORD DC, HAPPERFIELD L et al.: Comparative analysis of integrins in vitro and in vivo in uveal and cutaneous melanomas. Br. J. Cancer (1998) 77:522-529.
49. ARAP W, KOLONIN MG, TREPEL M et al.: Steps toward mapping the human vasculature by phage display. Nat. Med. (2002) 8:121-127.
50. ANDERSON SA, RADER RK, WESTLIN WF et al.: Magnetic resonance contrast enhancement of neovasculature with alpha v beta 3-targeted nanoparticles. Magn. Reson. Med. (2000) 44:433-439.
51. HAUBNER R, WESTER HJ, REUNING U et al.: Radiolabeled alpha v beta 3 integrin antagonists: A new class of tracers for tumor targeting. J. Nucl. Med. (1999) 40:1061-1071.
52. ARAP W, HAEDICKE W. BERNASCONI M et al.: Targeting the prostate for destruction through a vascular address. Proc. Natl. Acad. Sci. USA (2002) 99:1527-1531.
53. SIVOLAPENKO GB, SKARLOS D, PECTASIDES D et al.: Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing syntheic peptide. Eur. J. Nucl. Med. (1998) 25:1383-1389.
54. SIPKINS DA, CHERESH DA, KAZEMI MR, NEVIN LM, BEDNARSKI MD, LI KC: Detection of tumor angiogenesis in vivo by alpha v beta 3-targeted magnetic resonance imaging. Nat. Med. (1998) 4:623-626.
55. POSEY JA, KHAZAELI MB, DELGROSSO A et al.: A pilot trial of Vitaxin, a humanized anti-vitonectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother. Radiopharm. (2001) 16:125-132.
56. FRIEDLANDER M, THEESFELD CL, SUGITA M et al.: Involvement of integrin alpha v beta 3 and alpha v beta 5 in ocular neovascualar diseases. Proc. Natl. Acad. Sci. USA (1996) 93:9764-9769.
57. PREISSNER KT, KANSE HP, HAMMES HP: Integrin chatter and vascular function in diabetic retinopathy. Horm. Metab. Res. (1997) 29:643-645.
58. 3 requirement for sustained mitogen-activated protein kinase activated protein kinase activity during angiogenesis. J. Cell Biol. (1999) 14:1255-1263.
59. V integrins Science (1995) 27:1500-1502.
60. ELICEIRI BP, CHERESH D: The role of alpha v integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J. Clin. Invest. (1999) 103:1227-1230.
61. 3 inhibit retinal neovascularization in a murine model. Lab. Invest. (1996) 75:563-573.
62. 3 for angiogenesis. Science (1994) 264:569-571.
63. 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. (1995) 96:1815-1822.
64. KERR JS, WEXLER RS, MOUSA SA et al.: Novel small molecule αv integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res. (1999) 19:959-968.
65. 5 integrin receptor antagonist. Cancer Res. (2001) 61:2232-2238.
66. REYNOLDS LE, WYDER L, LIVLEY JC et al.: Enhance pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nat. Med. (2002) 8:27-34.
67. CHERESH D, STUPACK DG: Integrin- mediated death: An explanation of the integrin knockout phenotype? Nat. Med. (2002) 8:193-194.
68. HYNES RO: A reevaluation of integrins as regulators of angiogenesis. Nat. Med. (2002) 8:918-921.
69. PITTS WJ, WITYAK J, SMALLHEER JM et al.: Isoxazolines as potent antagonists of the integrin alpha v beta 3. J. Med. Chem. (2000) 43:27-40.
70. BATT DG, PETRAITIS JJ, HOUGHTON GC et al.: Disubstituted indazoles as potent antagonists of the integrin alpha v beta 3. J. Med. Chem. (2000) 43:41-58.
71. MILLER WH, ALBERTS DP, BHATNAGAR PK et al.: Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine gly-asp mimetic. J. Med. Chem. (2000) 43:22-26.
72. ALLMAN R, COWBURN P, MASON M: In vitro and in vivo effects of a cyclic peptide with affinity for the alpha v beta 3 integrin in human melanoma cells. Eur. J. Cancer (2000) 36:410-422.
73. 3 integrin and inhibits angiogenesis. J. Biol. Chem. (2001) 276:31959-31968.
74. HOEKSTRA WJ, POULTER BL: Combinatorial chemistry techniques applied to nonpeptide integrin antagonists. Curr. Med. Chem. (1998) 5:195-204.
75. PASCO S, HAN J, GILLERY P et al.: A specific sequence of the non-collagenous domain of the αv(IV) chain of Type IV collagen inhibits expression and activation of matrix metalloproteinases by tumor cells. Cancer Res. (2000) 60:467-473.
76. 3 integrin antagonist library. Bioorg. Med. Chem. Lett. (1997) 40:2289-2292.
77. DUGGAN DE, HUTCHINSON JH: Ligands to the integrin receptor alpha v beta 3. Expert Opin. Ther. Patents (2000) 10:1367-1383.
78. MILLER WH, KEENAN RM, WILLETTE RN, LARK MW: Identification and in vivo efficacy of small-molecule antagonists of integrin alpha v beta 3 (the vitronectin receptor). Drug Discov. Today (2000) 5:397-408.
79. ALBINI A, NOONAN D, SANTI L: Angiogenesis at the interface between basic and clinical research. Intern. J. Biol. Markers (1999) 14:202-206.
80. MEDIMMUNE. MedImmune initiates phaseI/II clinical study with Vitaxin. Expert Rev. Anticancer Ther. (2001) 1:166.
81. PATEL SR, JENKINS J, PAPADOPOLOUS N et al.: Pilot study of Vitaxin- an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer (2001) 92:1347-1348.